Protagonist Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Protagonist Therapeutics
PTGX Stock  USD 35.64  0.55  1.57%   
Protagonist Therapeutics financial statements provide useful quarterly and yearly information to potential Protagonist Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Protagonist Therapeutics financial statements helps investors assess Protagonist Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Protagonist Therapeutics' valuation are summarized below:
Gross Profit
434.4 M
Profit Margin
0.6334
Market Capitalization
2.2 B
Enterprise Value Revenue
4.0231
Revenue
434.4 M
We have found one hundred twenty available trending fundamental ratios for Protagonist Therapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Protagonist Therapeutics recent market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 2.5 B in 2025. Enterprise Value is likely to rise to about 2.4 B in 2025

Protagonist Therapeutics Total Revenue

456.15 Million

Check Protagonist Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagonist Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4 M, Interest Expense of 4.1 M or Selling General Administrative of 45.6 M, as well as many indicators such as Price To Sales Ratio of 23.7, Dividend Yield of 0.0 or PTB Ratio of 3.7. Protagonist financial statements analysis is a perfect complement when working with Protagonist Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Protagonist Therapeutics Correlation against competitors.
For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.

Protagonist Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets782 M744.7 M214 M
Slightly volatile
Total Current Liabilities29.9 M47.4 M20.9 M
Slightly volatile
Other Liabilities132.2 K139.2 K2.1 M
Very volatile
Property Plant And Equipment Net13.2 M12.6 M3.7 M
Slightly volatile
Accounts Payable2.3 M1.6 M1.7 M
Slightly volatile
Cash90.6 M97.2 M64.7 M
Slightly volatile
Non Current Assets Total160.7 M153.1 M23.8 M
Slightly volatile
Other Assets245.8 K258.8 K330.3 K
Slightly volatile
Cash And Short Term Investments215.9 M418.9 M150.8 M
Slightly volatile
Net Receivables12.5 M11.9 M3.8 M
Slightly volatile
Common Stock Shares Outstanding33.6 M65.1 M24.6 M
Slightly volatile
Short Term Investments337.7 M321.7 M97.9 M
Slightly volatile
Other Current Assets181.4 M172.7 M24.2 M
Slightly volatile
Other Stockholder Equity1.1 B1 B326.2 M
Slightly volatile
Total Liabilities112.7 M69.4 M78.1 M
Slightly volatile
Property Plant And Equipment Gross20.6 M19.6 M5.5 M
Slightly volatile
Total Current Assets621.2 M591.6 M190.2 M
Slightly volatile
Property Plant Equipment2.5 M1.8 M1.8 M
Slightly volatile
Non Currrent Assets Other147.5 M140.5 M18.5 M
Slightly volatile
Long Term Debt Total6.6 M11.3 M6.8 M
Slightly volatile
Capital Surpluse908.9 M865.6 M342.5 M
Slightly volatile
Current Deferred Revenue11.7 M18.9 M21.9 M
Slightly volatile
Net Invested Capital709.1 M675.3 M230.2 M
Slightly volatile
Net Working Capital273.9 M544.2 M189.1 M
Slightly volatile
Deferred Long Term Asset Charges526.4 K592.2 K645.7 K
Slightly volatile
Short Term Debt484.5 K510 K1.6 M
Slightly volatile
Short and Long Term Debt Total5.9 M10.9 M12.7 M
Slightly volatile
Capital Lease Obligations6.4 M10.9 M6.6 M
Slightly volatile

Protagonist Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization4 M3.8 M1.3 M
Slightly volatile
Selling General Administrative45.6 M43.5 M16.3 M
Slightly volatile
Other Operating Expenses90.9 M176.7 M70.7 M
Slightly volatile
Research Development80.1 M138.1 M56.9 M
Slightly volatile
Total Operating Expenses100.8 M181.6 M71.6 M
Slightly volatile
Net Interest Income27.6 M26.3 M5 M
Slightly volatile
Interest Income27.6 M26.3 M5 M
Slightly volatile
Non Operating Income Net Other4.8 M4.6 M1.6 M
Slightly volatile
Reconciled Depreciation2.5 M2.9 M1.5 M
Slightly volatile

Protagonist Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation39.4 M37.6 M11 M
Slightly volatile
Begin Period Cash Flow196.3 M187 M65.6 M
Slightly volatile
Other Cashflows From Financing Activities15 M25.9 M12.5 M
Slightly volatile
Depreciation1.9 M2.9 M1.4 M
Slightly volatile
Capital Expenditures752.7 K1.4 M592.2 K
Slightly volatile
Total Cash From Financing Activities24.6 M25.9 M57.6 M
Slightly volatile
End Period Cash Flow90.9 M97.5 M64.8 M
Slightly volatile
Change To Netincome29.2 M27.8 M10.5 M
Slightly volatile
Net Borrowings15.6 M16.7 M12.8 M
Slightly volatile
Exchange Rate Changes17.6 K19.8 K21.6 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio23.724.9569.6562
Very volatile
Days Sales Outstanding68.6772.28717
Very volatile
Stock Based Compensation To Revenue0.530.562.5899
Very volatile
Capex To Depreciation0.840.4680.8665
Slightly volatile
EV To Sales20.3221.3961.0935
Pretty Stable
Payables Turnover0.50.260.7162
Slightly volatile
Sales General And Administrative To Revenue0.610.644.8728
Very volatile
Research And Ddevelopement To Revenue2.192.320.0116
Very volatile
Capex To Revenue0.01110.01170.2867
Very volatile
Cash Per Share4.966.80424.9681
Slightly volatile
Days Payables Outstanding1.3 K1.5 K1.2 K
Slightly volatile
Current Ratio6.5512.48247.8779
Slightly volatile
Receivables Turnover4.975.2338.1915
Pretty Stable
Graham Number34.8733.212817.968
Slightly volatile
Capex Per Share0.0360.0220.0375
Slightly volatile
Revenue Per Share0.871.220.9734
Slightly volatile
Interest Debt Per Share0.230.17650.4658
Slightly volatile
Debt To Assets0.01390.01460.0737
Slightly volatile
Days Of Payables Outstanding1.3 K1.5 K1.2 K
Slightly volatile
Ebt Per Ebit1.111.10511.0622
Slightly volatile
Quick Ratio6.5912.48247.9084
Slightly volatile
Net Income Per E B T1.091.130.9988
Slightly volatile
Cash Ratio2.812.05184.317
Slightly volatile
Days Of Sales Outstanding68.6772.28717
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.80.99260.995
Slightly volatile
Fixed Asset Turnover33.7132.1120.4099
Very volatile
Debt Ratio0.01390.01460.0737
Slightly volatile
Price Sales Ratio23.724.9569.6562
Very volatile
Asset Turnover0.120.190.1222
Very volatile
Gross Profit Margin0.740.870.8947
Pretty Stable

Protagonist Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.5 B2.4 B626.6 M
Slightly volatile
Enterprise Value2.4 B2.3 B566.2 M
Slightly volatile

Protagonist Fundamental Market Drivers

Forward Price Earnings26.3852
Cash And Short Term Investments418.9 M

Protagonist Upcoming Events

20th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Protagonist Therapeutics Financial Statements

Protagonist Therapeutics investors use historical fundamental indicators, such as Protagonist Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagonist Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue18.9 M11.7 M
Total Revenue434.4 M456.2 M
Cost Of Revenue3 M2.8 M
Stock Based Compensation To Revenue 0.56  0.53 
Sales General And Administrative To Revenue 0.64  0.61 
Research And Ddevelopement To Revenue 2.30  2.19 
Capex To Revenue 0.01  0.01 
Revenue Per Share 1.22  0.87 
Ebit Per Revenue(1.40)(1.48)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CRMSalesforce
CCitigroup
GMGeneral Motors

Additional Tools for Protagonist Stock Analysis

When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY